
<h1 id="parathyroid">Parathyroid</h1>
<hr />

<h2 id="anatomy-and-physiology">Anatomy and Physiology</h2>
<p>Average 4 glands behind thyroid, each about size of grain; brown/fatty vascularized tissue, encapsulated  </p>

<ul>
  <li>Chief cell – produce PTH</li>
  <li>Oxyphil (oncocytic) cell – large, eosinophilic (pink), granular cytoplasm; lower activity (but more mitochondria) </li>
  <li>Solid nests of cells separated by fibrous/fatty tissue </li>
</ul>

<h2 id="electrolytes-and-hormones">Electrolytes and Hormones</h2>

<h3 id="calcium">Calcium</h3>
<p><em>Functions</em>: signal transduction, membrane potential, muscle contraction, co-factor; tightly regulated - PTH receptor (GPCR)<br />
<em>Distribution</em>: 99% in skeleton, 0.5% protein bound, 0.5% ionic; intake/loss about 1 g/day; low intracelluar, high extracellular </p>

<h3 id="parathyroid-hormone-pth">Parathyroid Hormone (PTH)</h3>
<p>PTH: amino acid 1-34 polypeptide active (teriparatide) 
<strong>Effects</strong> </p>

<ul>
  <li>bone turnover (osteoclast)</li>
  <li>renal Ca re-absorption (distal convoluted tubule) and phosphate secretion</li>
  <li>higher 1α-hydroxylase activity (increase calcitriol) → gut Ca absorption </li>
</ul>

<p>chronic high PTH – bone resorption (osteoclasts) </p>

<p><strong>PTH receptor mutations</strong>
Activating – Jansen’s metaphyseal chondroplasia (dwarfism) 
Inactivating – Blomstrand’s chondroplasia (defective bone maturation, early death) </p>

<p><strong>Ca sensing receptor mutation</strong> 
Inactivating – familial hypercalciuric hypercalcemia (FHH)  </p>

<h3 id="vitamin-d">Vitamin D</h3>

<p>important in rickets, osteomalacia, hypoPTH, and osteoporosis </p>

<ul>
  <li>Steroid hormone (cholesterol based)</li>
  <li>ergocalciferol added to milk   </li>
  <li>dihydrotachysterol used in nephrology </li>
  <li>UV: 85% from sun </li>
  <li>cholecalciferol based molecule </li>
  <li>25-hydroxy vit D: by liver, major circulating form</li>
  <li>1,25-dihydroxy vit D (calcitriol): by kidneys, activated vitamin D </li>
</ul>

<p><em>Effects</em> 
increase bone resorption/mineralization, Ca/PO4 absorption (GI) 
recommended 1000 IU/day  </p>

<h3 id="more-pharmacology">More Pharmacology</h3>

<p><strong>Bisphosphonates</strong>
Incorporates into bone. Inhibits osteoclasts 
zolendronate – used for malignancy, osteolytic bone lesions 
<em>Adverse effects</em>: headache, rash, abdominal discomfort, MSK/bone pain, diarrhea, loss of taste, gastric irritation, osteonecrosis of jaw </p>

<p><strong>Hormone Replacement Therapy</strong>
estrogen
to treat osteoporosis </p>

<p><strong>Selective estrogen receptor modifier (SERM)</strong>
raloxifene; mediates factors produced by osteoblast  </p>

<p><strong>Denosumab (Prolia)</strong> 
RANK-L inhibitor (receptor activator of nuclear factor κB ligand) – inhibit osteoclast action   </p>

<p><strong>Teriparatide (Forteo)</strong> 
recombinant PTH </p>

<p><strong>Calcimimetic</strong> 
cinacalcet (Sensipar) – allosteric activator of Ca sensing receptor on parathyroid chief cells leading to increased PTH secretion </p>

<p><strong>More</strong> </p>

<ul>
  <li>Thiazide diuretics reduce Ca excretion </li>
  <li>loop diuretics increase Ca excretion</li>
  <li>glucocorticoids increase bone resorption  </li>
  <li>fluoride in excess can lead to flurosis</li>
</ul>

<h2 id="hyperparathyroidism">Hyperparathyroidism</h2>
<p><strong>Symptoms</strong>: “abdominal groan, mental moan, breaking bone, kidney stone” </p>

<p>In secondary hyperparathyroidism: Osteititis fibrosa cystica and brown tumour of bone (hemorrhage) </p>

<p><strong>1°: high PTH</strong> 
<em>neoplasia</em> (focal): adenoma (80%), carcinoma (&lt;1%)</p>

<p><em>hyperplasia</em> (15%) – multiple glands </p>

<ul>
  <li>age, F:M = 3:1, 80% sporadic, 20% familial (MEN1/2A)  </li>
  <li>treatment: subtotal parathyroidectomy (leave part of 1 gland)</li>
</ul>

<p><strong>2°: adaptive increase in PTH</strong> 
chronic renal failure → hypocalcemia, hyperphosphate → high PTH 
other: Ca/vit D deficiency, severe hypomagnesemia   </p>

<h3 id="parathyroid-adenoma">Parathyroid adenoma</h3>
<p>benign, F:M = 4:1, usually single gland 
<em>pathology</em>: clonal proliferation of chief cells, encapsulated, displace normal tissue 
<em>treatment</em>: surgery (check another gland to rule out asymmetrical hyperplasia)</p>

<h3 id="parathyroid-carcinoma">Parathyroid carcinoma</h3>
<p><em>epidemiology</em>: uncommon, older individuals, severe hypercalcemia, larger, infiltrative (neck dissection harder) 
<em>pathology</em>: nests of malignant cells separated by fibrous bands; lymphovascular invasion 
<em>treatment</em>: surgery en bloc resection including ipsilateral thyroid, 50% cure, recurrences within 3 years  </p>

<h2 id="hypoparathyroidism">Hypoparathyroidism</h2>
<p><em>Symptoms</em>
hypocalcemia – neuromuscular excitability, irritable/depression, calcification of basal ganglia, cardiac conduction problems
low PTH and low Ca<br />
<em>Causes</em>: usually iatrogenic, occasionally autoimmune, congenital agenesis (DiGeorge syndrome)  </p>

